130 related articles for article (PubMed ID: 17146978)
41. An adaptive approach for bivariate phase II clinical trial designs.
Wu C; Liu A
Contemp Clin Trials; 2007 Jul; 28(4):482-6. PubMed ID: 17303476
[TBL] [Abstract][Full Text] [Related]
42. Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group.
Francart J; Legrand C; Sylvester R; Van Glabbeke M; van Meerbeeck JP; Robert A
J Clin Oncol; 2006 Jul; 24(19):3007-12. PubMed ID: 16809726
[TBL] [Abstract][Full Text] [Related]
43. Continuous and group sequential conditional probability ratio tests for phase II clinical trials.
Tan M; Xiong X
Stat Med; 1996 Oct; 15(19):2037-51. PubMed ID: 8896138
[TBL] [Abstract][Full Text] [Related]
44. Novel designs and end points for phase II clinical trials.
Adjei AA; Christian M; Ivy P
Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
[TBL] [Abstract][Full Text] [Related]
45. Optimising the design of phase II oncology trials: the importance of randomisation.
Ratain MJ; Sargent DJ
Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
[TBL] [Abstract][Full Text] [Related]
46. Improved confidence intervals for a binomial parameter following a group sequential phase II clinical trial.
Chang MN
Stat Med; 2004 Sep; 23(18):2817-26. PubMed ID: 15344188
[TBL] [Abstract][Full Text] [Related]
47. Interval and point estimation in adaptive Phase II trials with binary endpoint.
Nhacolo A; Brannath W
Stat Methods Med Res; 2019 Sep; 28(9):2635-2648. PubMed ID: 29921157
[TBL] [Abstract][Full Text] [Related]
48. An exact method for analysis following a two-stage phase II cancer clinical trial.
Jovic G; Whitehead J
Stat Med; 2010 Dec; 29(30):3118-25. PubMed ID: 21170906
[TBL] [Abstract][Full Text] [Related]
49. Examining heterogeneity in phase II trial designs may improve success in phase III.
Tuma RS
J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788
[No Abstract] [Full Text] [Related]
50. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
[TBL] [Abstract][Full Text] [Related]
51. A hybrid Bayesian adaptive design for dose response trials.
Chang M; Chow SC
J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
[TBL] [Abstract][Full Text] [Related]
52. Analysis of time-to-event data under a two-stage survival adaptive design in clinical trials.
Lu Q; Tse SK; Chow SC
J Biopharm Stat; 2010 Jul; 20(4):705-19. PubMed ID: 20496201
[TBL] [Abstract][Full Text] [Related]
53. Multinomial phase II trial designs.
Freidlin B; Dancey J; Korn EL; Zee B; Eisenhauer E
J Clin Oncol; 2002 Jan; 20(2):599. PubMed ID: 11786592
[No Abstract] [Full Text] [Related]
54. Bayesian approach to two-stage phase II trial.
Pepple PA; Choi SC
J Biopharm Stat; 1997 May; 7(2):271-86. PubMed ID: 9136069
[TBL] [Abstract][Full Text] [Related]
55. A two-stage phase II trial design utilizing both primary and secondary endpoints.
Lin X; Allred R; Andrews G
Pharm Stat; 2008; 7(2):88-92. PubMed ID: 17252536
[TBL] [Abstract][Full Text] [Related]
56. Optimal two-stage randomized multinomial designs for Phase II oncology trials.
Sun LZ; Chen C; Patel K
J Biopharm Stat; 2009; 19(3):485-93. PubMed ID: 19384690
[TBL] [Abstract][Full Text] [Related]
57. An adjustment for patient heterogeneity in the design of two-stage phase II trials.
Sposto R; Gaynon PS
Stat Med; 2009 Sep; 28(20):2566-79. PubMed ID: 19521973
[TBL] [Abstract][Full Text] [Related]
58. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
Zhao L; Woodworth G
Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
[TBL] [Abstract][Full Text] [Related]
59. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
60. Multinomial phase II cancer trials incorporating response and early progression.
Zee B; Melnychuk D; Dancey J; Eisenhauer E
J Biopharm Stat; 1999 May; 9(2):351-63. PubMed ID: 10379698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
